Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Depomed Inc (NASDAQ:DEPO)

18.97
Delayed Data
As of 3:59pm ET
 -0.28 / -1.45%
Today’s Change
12.25
Today|||52-Week Range
33.11
+4.63%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.2B

Company Description

Depomed, Inc. manufactures and distributes pharmaceutical products. It is a pharmaceutical company, which focuses on the pain and other central nervous system conditions. The company product brands include Gralise, Zipsor, Lazanda, CAMBIA, NUCYNTA ER and NUCYNTA. It has developed and licensed a drug-delivery technology, Acuform. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.

Contact Information

Depomed, Inc.
7999 Gateway Boulevard
Newark California 94560
P:(510) 744-8000
Investor Relations:
(650) 462-5900

Employees

Shareholders

Other institutional65.28%
Mutual fund holders47.13%
Individual stakeholders11.93%

Top Executives

James A. SchoeneckPresident, Chief Executive Officer & Director
August J. MorettiCFO, Senior VP & Head-Investor Relations
Gerd G. KochendoerferVice President-Technical Development & Quality
G. Srinivas RaoChief Medical Officer & Senior Vice President
Matthew M. GoslingSenior Vice President & General Counsel